Welcome to our dedicated page for Quotient news (Ticker: QTNT), a resource for investors and traders seeking the latest updates and insights on Quotient stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Quotient's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Quotient's position in the market.
Quotient Limited (NASDAQ:QTNT) has appointed Dr. Christine Ginocchio as Chief Scientific & Medical Officer, bringing over 40 years of experience in clinical diagnostics and laboratory management. Dr. Ginocchio will focus on launching the MosaiQ solution and enhancing collaboration with the scientific community to improve clinical outcomes. She previously served at bioMérieux/BioFire, overseeing medical affairs. In connection with her appointment, Quotient granted her performance-based restricted share units and options linked to financial targets.
Quotient Limited (NASDAQ:QTNT) has initiated the review process for its Expanded Immunohematology (IH) technical file dossier by the European notified body, with part I submitted in September. CEO Manuel O. Méndez expressed satisfaction with this progress and anticipates CE Mark approval by year-end, paving the way for a commercial launch in Europe. The company's MosaiQ microarray technology aims to enhance diagnostic efficiency, offering significant workflow improvements and cost savings for labs worldwide.
Quotient Limited (NASDAQ:QTNT) has appointed Christian Albrich as Chief People Officer. Albrich, previously with Galderma and Actelion Pharmaceuticals, will play a crucial role in transforming Quotient from a development-focused to a commercially driven organization. His compensation package includes 60,169 performance-based restricted share units and options for shares, contingent on achieving specific financial targets. Quotient aims to enhance its transfusion diagnostics capabilities through its proprietary MosaiQ technology, promising improved efficiencies and cost savings in laboratory testing.
Quotient Limited (NASDAQ:QTNT) announced the resignation of Chief Commercial Officer Jeremy Stackawitz, effective October 5, 2021. Stackawitz contributed significantly to Quotient's strategic vision over his 12-year tenure. The company is searching for a qualified replacement to ensure continued business execution. Quotient specializes in transfusion diagnostics and is known for its MosaiQ technology, a fully automated testing platform designed to enhance efficiency and reduce costs in laboratories worldwide.
Quotient reported significant progress in Q1 FY22 with its MosaiQ transfusion diagnostics. The expanded immunohematology (IH) microarray achieved over 99% concordance in preliminary trials, indicating successful performance enhancements. Commercially, 25 distributors have been established, and several customer evaluations are in progress. Financially, Quotient's balance sheet strengthened with $105 million in convertible debt. Despite a 2% rise in total product sales ($9 million), OEM sales dropped 5%. The company expects FY22 product sales of Alba reagents to be between $35.5 million and $36.5 million.
Quotient Limited (NASDAQ:QTNT) announced the appointment of Dr. Michael Hausmann as Chief Technology Officer effective August 1, 2021. As part of his induction, the company granted him equity awards totaling CHF 1,190,400 ($1,313,907), which include performance-based restricted share units, restricted share units, and share options. The vesting of these awards is contingent on Dr. Hausmann's ongoing service and the achievement of specific financial targets.
Quotient, known for its MosaiQ technology, aims to revolutionize diagnostics while contributing to the fight against COVID-19.
Quotient Limited (NASDAQ:QTNT) will release its fiscal first quarter financial results for the period ending June 30, 2021, before market opening on August 5, 2021. A conference call is scheduled for the same day at 8:00 a.m. ET to discuss the results. Quotient, a diagnostics company specializing in transfusion diagnostics, is known for its MosaiQ technology, which offers automated testing solutions. Additionally, it has developed a COVID-19 Antibody Microarray that has received CE marking and U.S. FDA Emergency Use Authorization.
Quotient Limited (NASDAQ:QTNT) announced the resignation of Chief Financial Officer Peter Buhler, effective December 31, 2021, as he transitions to another company. CEO Manuel O. Méndez expressed gratitude for Buhler's contributions to Quotient's strategic vision. The company has begun the search for a qualified replacement CFO to ensure continuity in executing its financial strategies. Quotient focuses on innovative diagnostic solutions, notably its MosaiQ technology, which aims to enhance laboratory efficiencies worldwide.
Quotient Limited (NASDAQ: QTNT) has appointed Dr. Michael Hausmann as CTO to enhance innovation and drive the commercialization of its MosaiQ transfusion diagnostics products. The company is progressing with European field trials set to start in June 2021 and exploring new partnerships to expand its offerings. Alba by Quotient reported a strong revenue growth of 9.2% for FY21, exceeding guidance. The company bolstered its cash position with a $95 million placement of Convertible Senior Notes. As of May 2021, cash and equivalents were $168 million.
Quotient Limited (NASDAQ:QTNT), a diagnostics firm, will participate in two investor conferences in June 2021. The Jefferies Virtual Healthcare Conference is scheduled for June 2, 2021, at 9:00am ET, while the Goldman Sachs 42nd Annual Global Healthcare Conference will take place on June 9, 2021, at 8:00am ET. Both presentations will be available via webcast on the company’s investor relations page, with replays archived for 90 days. Quotient is known for its MosaiQ technology, enhancing diagnostic efficiency, including its COVID-19 Antibody Microarray, which is CE marked and FDA authorized.
